BCYC BICYCLE THERAPEUTICS plc
Price (delayed)
$8.05
Market cap
$557.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.9
Enterprise value
-$318.45M
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short
Highlights
BCYC's debt has dropped by 90% year-on-year and by 28% since the previous quarter
BICYCLE THERAPEUTICS's EPS has increased by 43% YoY and by 11% from the previous quarter
BCYC's equity has surged by 114% year-on-year but it is down by 4.6% since the previous quarter
BICYCLE THERAPEUTICS's quick ratio has surged by 72% YoY but it has decreased by 19% QoQ
Key stats
What are the main financial stats of BCYC
Market
Valuations
Earnings
Shares outstanding
69.2M
Market cap
$557.08M
Enterprise value
-$318.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.7
Price to sales (P/S)
13.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.03
Revenue
$35.28M
Gross profit
$35.28M
Operating income
-$209.87M
Net income
-$169.03M
EBIT
-$172.07M
EBITDA
-$164.89M
Free cash flow
-$165.96M
Per share
Balance sheet
Liquidity
EPS
-$2.9
EPS diluted
-$2.9
Free cash flow per share
-$2.85
Book value per share
$11.49
Revenue per share
$0.61
TBVPS
$16.44
Total assets
$956.87M
Total liabilities
$163.81M
Debt
$3.99M
Equity
$793.06M
Working capital
$861.38M
Debt to equity
0.01
Current ratio
13.81
Quick ratio
13.61
Net debt/EBITDA
5.31
Margins
Efficiency
Dividend
EBITDA margin
-467.4%
Gross margin
100%
Net margin
-479.2%
Operating margin
-595%
Return on assets
-19%
Return on equity
-23.7%
Return on invested capital
-323.7%
Return on capital employed
-19.3%
Return on sales
-487.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCYC stock price
How has the BICYCLE THERAPEUTICS stock price performed over time
Intraday
2.55%
1 week
-7.79%
1 month
-26.62%
1 year
-66.08%
YTD
-42.5%
QTD
-5.18%
Financial performance
How have BICYCLE THERAPEUTICS's revenue and profit performed over time
Revenue
$35.28M
Gross profit
$35.28M
Operating income
-$209.87M
Net income
-$169.03M
Gross margin
100%
Net margin
-479.2%
BICYCLE THERAPEUTICS's gross profit has increased by 31% YoY but it has decreased by 4.4% QoQ
BCYC's revenue is up by 31% YoY but it is down by 4.4% QoQ
BCYC's net margin is up by 28% year-on-year but it is down by 6% since the previous quarter
The operating margin has grown by 15% YoY but it has contracted by 12% from the previous quarter
Growth
What is BICYCLE THERAPEUTICS's growth rate over time
Valuation
What is BICYCLE THERAPEUTICS stock price valuation
P/E
N/A
P/B
0.7
P/S
13.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-9.03
BICYCLE THERAPEUTICS's EPS has increased by 43% YoY and by 11% from the previous quarter
BCYC's equity has surged by 114% year-on-year but it is down by 4.6% since the previous quarter
The stock's P/B is 79% below its 5-year quarterly average of 3.2 and 62% below its last 4 quarters average of 1.8
The P/S is 73% less than the 5-year quarterly average of 48.5 and 56% less than the last 4 quarters average of 29.4
BCYC's revenue is up by 31% YoY but it is down by 4.4% QoQ
Efficiency
How efficient is BICYCLE THERAPEUTICS business performance
The ROE has soared by 59% YoY and by 13% from the previous quarter
The ROA has grown by 44% YoY and by 9% from the previous quarter
The company's return on invested capital fell by 32% YoY and by 15% QoQ
BICYCLE THERAPEUTICS's ROS has increased by 25% YoY but it has decreased by 8% from the previous quarter
Dividends
What is BCYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCYC.
Financial health
How did BICYCLE THERAPEUTICS financials performed over time
BICYCLE THERAPEUTICS's quick ratio has surged by 72% YoY but it has decreased by 19% QoQ
BCYC's current ratio has surged by 71% year-on-year but it is down by 19% since the previous quarter
BCYC's debt is 99% smaller than its equity
BCYC's equity has surged by 114% year-on-year but it is down by 4.6% since the previous quarter
BICYCLE THERAPEUTICS's debt to equity has plunged by 91% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.